• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Rituximab Hits Endpoints for New Indication

Rituximab Hits Endpoints for New Indication

February 5, 2008
CenterWatch Staff

Roche issued positive results from a phase III trial of MabThera (Rituxan, rituximab) as a first-line therapy for rheumatoid arthritis. This international, randomized, placebo controlled, double blind, parallel group study was dubbed SERENE (Study Evaluating Rituximab’s Efficacy in methotrexate iNadequate rEsponders).

The trial enrolled five hundred and nine subjects who received either MabThera (500 mg or 1000 mg) or placebo by intravenous infusion on days one and fifteen, plus weekly methotrexate (MTX).

The primary endpoint was the percentage of subjects who had at least a 20% reduction in a number of symptoms and measures of disease, measured via the American College of Rheumatology assessment (ACR20) at week twenty four.  The primary endpoint was reached; a significantly greater proportion of subjects treated with MabThera/MTX achieved an improvement in disease signs and symptoms compared to those treated with MTX alone. Treatment was well tolerated, with a profile consistent with previous studies.

“These data support the potential for MabThera to be used earlier in the course of treatment for RA. The results are encouraging and show that MabThera represents a promising alternative to current treatment options in patients who have an inadequate response to traditional therapy”, said William Burns, chief executive officer of Roche's pharmaceuticals division.

Rituximab is already approved rheumatoid arthritis in combination with methotrexate. It is also approved certain forms of B-cell non-Hodgkin's lymphoma (NHL).

Based on the results, Roche intends to file for FDA approval of MabThera as a first-line therapy.

Rituximab is a (mouse/human chimeric) anti-CD20 monoclonal antibody developed and launched by IDEC Pharmaceuticals (now Biogen Idec), Genentech, Roche Holding and Zenyaku Kogyo.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing